Company intelligence / Profile preview
Affimed
Heidelberg/Mannheim*, Baden-Württemberg, Germanyaffimed.com ↗
- Ownership
- Public · AFMD
- Employees
- ~200
- Development stage
- Other
01
Overview
Affimed’s clinical programs have shown promising efficacy and safety. Acimtamig combined with NK cells has demonstrated high objective response rates in heavily pretreated Hodgkin lymphoma patients with a manageable safety profile. AFM24 has shown compelling responses in refractory NSCLC patients, particularly those with wild-type EGFR. AFM28 has reached the final dose level in its escalation study for AML[3][5].
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodies (Innate Cell Engagers/ICE®)Tetravalent bispecific antibodies (TandAb technology)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Artiva Biotherapeutics (“AlloNK” allogeneic NK cell therapy)[5]Select pharmaceutical companies—details not fully specified[1]
Beyond the preview
Go deeper on Affimed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affimed.